Chinese researchers have successfully engineered the SPARK-seq platform, a groundbreaking innovation that seamlessly combines CRISPR gene-editing technology, single-cell transcriptomics, and extensive aptamer sequencing on a single-cell basis. This integration facilitates the swift identification of cell membrane surface markers and the concurrent acquisition of targeted nucleic acid aptamer probes. When juxtaposed with conventional methodologies, the SPARK-seq platform exhibits a remarkable surge in screening efficiency, exceeding a hundredfold increase. It possesses the capability to accurately pinpoint potential cancer biomarkers and therapeutic targets, thereby paving the way for innovative treatment strategies for a myriad of diseases that currently lack effective interventions due to elusive targets. The groundbreaking research was published online in the esteemed "Science" journal on January 1, 2026.